For years, Bayer AG has been locked in courtroom combat over Roundup, the weedkiller inherited through its acquisition of Monsanto Co. Now the company is floating what it frames as a long-awaited endgame: a proposed $7.25 billion nationwide settlement designed to quiet both current and future claims that Roundup exposure led to non-Hodgkin lymphoma.
The price tag is eye-catching. The ambition is even bigger.
What’s On The Table?
The proposal, still awaiting judicial approval, would stretch payments over as long as 21 years. It envisions a structured compensation program for individuals who say they developed non-Hodgkin lymphoma after exposure to Roundup.
Payouts would vary sharply. A younger person with documented occupational exposure and an aggressive diagnosis could see an average payment of about $165,000. At the other end of the scale, someone over 78 with a qualifying diagnosis would receive $10,000.
The deal aims to sweep in the bulk of the roughly 65,000 cases pending in state and federal courts — and, crucially, to capture future claimants. Roundup’s active ingredient, glyphosate, remained in residential products until 2023. Given that non-Hodgkin lymphoma can take a decade or more to surface, Bayer is trying to fence off claims that haven’t even been filed yet.
A Settlement Without a Headcount
One key unknown: how many plaintiffs will sign on.
Bayer has reserved the right to walk away if participation falls short, but it has not disclosed what “enough” looks like. Several law firms involved in negotiations have voiced support, yet the company has not detailed how many clients are formally backing the proposal.
Not all corners of the plaintiffs’ bar are aligned. Some firms are still studying the terms; at least one has indicated opposition. Critics point to the unusual structure — creating a new class action framework that could supersede ongoing lawsuits — as a potential flashpoint when the proposal faces judicial scrutiny.
The 21-Year Bet
The long timeline is central to Bayer’s strategy. The settlement would fund a rolling claims system and require ongoing outreach to alert potential claimants. Anyone diagnosed would have two years from that diagnosis to decide whether to join.
Bayer is wagering that future claimants will prefer predictable compensation over the gamble of a jury trial. History shows that gamble can swing wildly. The company has notched courtroom wins, but it has also absorbed bruising verdicts, including a $332 million award in California in 2023 and a $2.1 billion judgment from a Georgia jury in 2025.
Opt-outs remain possible. Even if the deal is approved, plaintiffs can reject it and pursue litigation independently. That means the courtroom door would not be fully shut.
The Supreme Court Wild Card
Hovering over the settlement is a pivotal case before the Supreme Court of the United States. Oral arguments are scheduled for April 27. The justices will consider whether federal pesticide regulations shield Bayer from state-law claims alleging a failure to warn about cancer risks.
A ruling in Bayer’s favor could knock out thousands of cases built on that theory. A loss would leave the company defending claims in trial courts across the country. Either way, the proposed settlement appears designed as insurance — a hedge against legal uncertainty.
Closure or Just Another Chapter?
The deal does not guarantee finality. It could unravel if participation is too thin or if a court declines to certify it. Even if approved, some plaintiffs will likely opt out.
If the Supreme Court sides with Bayer, pressure on claimants to accept structured payouts could intensify. If not, the settlement may look less like a finishing move and more like another costly maneuver in a saga that has already stretched across courtrooms nationwide.
For Bayer, the $7.25 billion question isn’t just about money. It’s about whether this structure can finally impose order on a legal battle that has refused to settle quietly.
